- Home
- LVS vs DXCM Comparison
LVS vs DXCM Comparison
Compare LVS & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVS
- DXCM
- Stock Information
- Founded
- LVS 1988
- DXCM 1999
- Country
- LVS United States
- DXCM United States
- Employees
- LVS N/A
- DXCM N/A
- Industry
- LVS Hotels/Resorts
- DXCM Medical/Dental Instruments
- Sector
- LVS Consumer Discretionary
- DXCM Health Care
- Exchange
- LVS Nasdaq
- DXCM Nasdaq
- Market Cap
- LVS 32.3B
- DXCM 35.7B
- IPO Year
- LVS 2004
- DXCM 2005
- Fundamental
- Price
- LVS $44.03
- DXCM $88.78
- Analyst Decision
- LVS Buy
- DXCM Strong Buy
- Analyst Count
- LVS 14
- DXCM 17
- Target Price
- LVS $59.54
- DXCM $99.06
- AVG Volume (30 Days)
- LVS 6.8M
- DXCM 3.4M
- Earning Date
- LVS 04-16-2025
- DXCM 02-13-2025
- Dividend Yield
- LVS 2.27%
- DXCM N/A
- EPS Growth
- LVS 22.50
- DXCM 9.35
- EPS
- LVS 1.96
- DXCM 1.42
- Revenue
- LVS $11,298,000,000.00
- DXCM $4,033,000,000.00
- Revenue This Year
- LVS $9.91
- DXCM $16.44
- Revenue Next Year
- LVS $5.62
- DXCM $15.78
- P/E Ratio
- LVS $22.46
- DXCM $62.34
- Revenue Growth
- LVS 8.93
- DXCM 11.34
- 52 Week Low
- LVS $36.62
- DXCM $62.34
- 52 Week High
- LVS $56.61
- DXCM $142.00
- Technical
- Relative Strength Index (RSI)
- LVS 47.36
- DXCM 57.72
- Support Level
- LVS $41.15
- DXCM $83.20
- Resistance Level
- LVS $44.36
- DXCM $93.25
- Average True Range (ATR)
- LVS 1.18
- DXCM 2.20
- MACD
- LVS 0.42
- DXCM -0.09
- Stochastic Oscillator
- LVS 62.77
- DXCM 55.52
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore toward the end of 2028. Its Venetian and Palazzo Las Vegas assets in the U.S. were sold to Apollo and VICI in 2022. With the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.